These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 16904298)
21. Antipsychotic treatment in obsessive-compulsive disorder: a literature review. Keuneman RJ; Pokos V; Weerasundera R; Castle DJ Aust N Z J Psychiatry; 2005 May; 39(5):336-43. PubMed ID: 15860020 [TBL] [Abstract][Full Text] [Related]
22. [The role of drug therapy in the treatment of obsessive-compulsive disorders]. Teeuwisse JM; Nolen WA Ned Tijdschr Geneeskd; 1989 Dec; 133(52):2605-8. PubMed ID: 2575230 [No Abstract] [Full Text] [Related]
23. Clinically relevant interactions between newer antidepressants and second-generation antipsychotics. Spina E; de Leon J Expert Opin Drug Metab Toxicol; 2014 May; 10(5):721-46. PubMed ID: 24494611 [TBL] [Abstract][Full Text] [Related]
24. Creating more effective antidepressants: clues from the clinic. Rasmussen K Drug Discov Today; 2006 Jul; 11(13-14):623-31. PubMed ID: 16793531 [TBL] [Abstract][Full Text] [Related]
25. Quetiapine in treatment-resistant obsessive-compulsive disorder. Cohen LS J Am Acad Child Adolesc Psychiatry; 2003 Jun; 42(6):623-4. PubMed ID: 12921466 [No Abstract] [Full Text] [Related]
26. D-Cycloserine Augmentation of Exposure-Based Cognitive Behavior Therapy for Anxiety, Obsessive-Compulsive, and Posttraumatic Stress Disorders: A Systematic Review and Meta-analysis of Individual Participant Data. Mataix-Cols D; Fernández de la Cruz L; Monzani B; Rosenfield D; Andersson E; Pérez-Vigil A; Frumento P; de Kleine RA; Difede J; Dunlop BW; Farrell LJ; Geller D; Gerardi M; Guastella AJ; Hofmann SG; Hendriks GJ; Kushner MG; Lee FS; Lenze EJ; Levinson CA; McConnell H; Otto MW; Plag J; Pollack MH; Ressler KJ; Rodebaugh TL; Rothbaum BO; Scheeringa MS; Siewert-Siegmund A; Smits JAJ; Storch EA; Ströhle A; Tart CD; Tolin DF; van Minnen A; Waters AM; Weems CF; Wilhelm S; Wyka K; Davis M; Rück C; ; Altemus M; Anderson P; Cukor J; Finck C; Geffken GR; Golfels F; Goodman WK; Gutner C; Heyman I; Jovanovic T; Lewin AB; McNamara JP; Murphy TK; Norrholm S; Thuras P JAMA Psychiatry; 2017 May; 74(5):501-510. PubMed ID: 28122091 [TBL] [Abstract][Full Text] [Related]
28. Drug treatment of obsessive-compulsive disorder. Kellner M Dialogues Clin Neurosci; 2010; 12(2):187-97. PubMed ID: 20623923 [TBL] [Abstract][Full Text] [Related]
29. Can Atypical Antipsychotic Augmentation Reduce Subsequent Treatment Failure More Effectively Among Depressed Patients with a Higher Degree of Treatment Resistance? A Meta-Analysis of Randomized Controlled Trials. Wang HR; Woo YS; Ahn HS; Ahn IM; Kim HJ; Bahk WM Int J Neuropsychopharmacol; 2015 Mar; 18(8):. PubMed ID: 25770098 [TBL] [Abstract][Full Text] [Related]
30. Role and clinical implications of atypical antipsychotics in anxiety disorders, obsessive-compulsive disorder, trauma-related, and somatic symptom disorders: a systematized review. Albert U; Carmassi C; Cosci F; De Cori D; Di Nicola M; Ferrari S; Poloni N; Tarricone I; Fiorillo A Int Clin Psychopharmacol; 2016 Sep; 31(5):249-58. PubMed ID: 26974213 [TBL] [Abstract][Full Text] [Related]
32. [Resistance and refractoriness in obsessive-compulsive disorder]. Ferrão YA; Diniz JB; Lopes AC; Shavitt RG; Greenberg B; Miguel E Braz J Psychiatry; 2007 Oct; 29 Suppl 2():S66-76. PubMed ID: 18172943 [TBL] [Abstract][Full Text] [Related]
33. Protocol for a Systematic Review and Meta-Analysis of Lithium, Anticonvulsive or atypical antipsychotic Drugs for Treatment of Refractory Obsessive-Compulsive Disorder. Soleimani R; Jalali MM; Keshtkar A; Jalali SM J Med Life; 2017; 10(4):208-215. PubMed ID: 29362595 [TBL] [Abstract][Full Text] [Related]